Skip to main content

Table 4 Multivariable Cox regression analysis of all-cause death in patients with atrial fibrillation, eGFR as a continues variable

From: Impact of estimated glomerular filtration rate on long-term clinical outcomes among Chinese patients with atrial fibrillation

Variable HR represents HR (95%CI) P value
Total population    
 Age Per 1-year increment 1.018 (0.999–1.038) 0.066
 Male Versus female 2.418 (1.445–4.046) 0.001
 Duration of AF     < 0.001
  Persistent Versus paroxysmal 0.781 (0.352–1.737) 0.545
  Permanent Versus paroxysmal 2.379 (1.156–4.896) 0.019
 Warfarin Yes versus no 1.200 (0.661–2.179) 0.548
 TiTR  ≥ 66% versus < 66% 0.571 (0.137–1.656) 0.243
 eGFR Per 1 ml/(min·1.73 m2) increment 0.984 (0.972–0.995) 0.006
Individuals with EHRA Type 1 VHDs
 Age Per 1-year increment 1.044 (0.997–1.092) 0.067
 Male Versus female 1.817 (0.687–4.808) 0.229
 Duration of AF    0.277
  Persistent Versus paroxysmal 1.994 (0.196–20.257) 0.560
  Permanent Versus paroxysmal 3.937 (0.496–31.278) 0.195
 TiTR  ≥ 66% versus < 66% 0.491 (0.124–1.945) 0.311
 Warfarin Yes versus no 0.949 (0.334–2.700) 0.922
 eGFR Per 1 ml/(min·1.73 m2) increment 0.988 (0.967–1.010) 0.281
Individuals with EHRA Type 2 VHDs
 Age Per 1-year increment 1.003 (0.976–1.093) 0.269
 Male Versus female 1.439 (0.323–6.413) 0.633
 Duration of AF    0.145
  Persistent Versus paroxysmal 33.672 (1.001–1132.496) 0.050
  Permanent Versus paroxysmal 7.210 (0.544–95.538) 0.134
 CHA2DS2-VASc score Per 1 score increment 0.482 (0.214–1.089) 0.079
 Warfarin Yes versus no 1.122 (0.196–6.422) 0.897
 eGFR Per 1 ml/(min·1.73 m2) increment 1.000 (0.965–1.037) 0.985
Individuals without VHDs    
 Age Per 1-year increment 0.991 (0.961–1.022) 0.568
 Male Versus female 3.936 (1.780–8.706) 0.001
 Duration of AF    0.003
  Persistent Versus paroxysmal 0.561 (0.223–1.412) 0.220
  Permanent Versus paroxysmal 1.866 (0.769–4.528) 0.168
 CHA2DS2-VASc score Per 1 score increment 1.136 (0.927–1.392) 0.217
 Warfarin Yes versus no 1.270 (0.528–3.053) 0.594
 eGFR Per 1 ml/(min·1.73 m2) increment 0.975 (0.959–0.992) 0.003
  1. Models were adjusted by age, sex (male vs female), duration of AF, use of warfarin, TiTR (if available), CHA2DS2-VASc score (if available) and eGFR. VHDs indicates valvular heart diseases
  2. CHA2DS2-VASc score was calculated by congestive heart failure, hypertension, age ≥ 75 years (doubled), diabetes mellitus, prior stroke or TIA (doubled), vascular disease, age 65 to74 years, female sex
  3. AF indicates atrial fibrillation
  4. TiTR time in therapeutic range, CI confidential interval, HR hazard ratio, eGFR estimated Glomerular filtration rate